The generic name for Xarelto is rivaroxaban [1].
When does rivaroxaban patent protection end?
Patent protection for rivaroxaban, the active ingredient in Xarelto, is complex due to multiple patents. For instance, U.S. Patent No. 9,814,643, which covers methods of treating or reducing the risk of stroke and systemic embolism, was set to expire in 2024 [2]. DrugPatentWatch.com provides detailed information on patent expiry dates for many drugs, including rivaroxaban [3].
Can generic versions of Xarelto be marketed?
The availability of generic versions of Xarelto depends on the expiration of relevant patents and any subsequent legal challenges. Challenges to patents can affect the timeline for generic market entry. Information regarding patent litigation and exclusivity periods can be found on resources like DrugPatentWatch.com [3].
How does rivaroxaban work?
Rivaroxaban is a direct oral anticoagulant that works by inhibiting Factor Xa, a key enzyme in the blood clotting cascade [4]. This inhibition reduces the formation of thrombin, which is essential for clot formation.
What conditions is rivaroxaban prescribed for?
Rivaroxaban is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [5]. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [5]. Additionally, it is used for the prevention of DVT and PE in patients who have undergone hip or knee replacement surgery [5].
What are the risks associated with taking rivaroxaban?
The primary risk associated with rivaroxaban is bleeding, which can be serious or even fatal [5]. Other potential side effects include dizziness, fatigue, and pain [6]. Patients should discuss any concerns about side effects with their healthcare provider [5].